Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATR 1072 · 1 trial · 4 indications
Incidence and severity of treatment-emergent adverse events (TEAEs).
| Arm | Type | Description |
|---|---|---|
| Part A - MAD Dose Escalation Description Three sequential ascending dose | EXPERIMENTAL | Three sequential ascending dose cohorts (Dose Level 1, Dose Level 2 and Dose Level 3) with approximately 4 evaluable participants per cohort. ATR 1072 administered intravenously (IV) every 6 weeks (Q6W) for up to 8 doses (48-week treatment period). |
| Part B - Expansion Cohort at the Recommended Phase 2 Dose | EXPERIMENTAL | Approximately 25 participants enrolled at the recommended phase 2 dose determined in Part A. ATR 1072 administered IV Q6W to further evaluate safety, PK, and pharmacodynamics. |
| Name | Type | Description |
|---|---|---|
| ATR 1072 | DRUG | ATR 1072 is an investigational therapy that delivers an siRNA to reduce PRKAG2 gene expression. Administered as an intravenous (IV) infusion every 6 weeks (Q6W). Formulated as a sterile liquid for injection. |
Inclusion Criteria: 1. Adults 18 to 65 years of age. 2. Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing. 3. Clinical manifestations consistent with PRKAG2 Syndrome. 4. Able and willing to comply with study procedures. 5. Able and will...
ATR 1072 is an investigational small molecule developed by Atrium Therapeutics, Inc. for Cardiac Glycogenosis, a neurological therapeutic area condition. It is currently in Phase 1 clinical development and is being studied in participants with PRKAG2 syndrome, a genetic disorder that can cause hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome.
ATR 1072 is being developed for Cardiac Glycogenosis, specifically in participants with PRKAG2 syndrome. The Phase 1 trial enrolls adults with this condition, which can include hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome. It is investigational and has not been approved for any use.
ATR 1072 targets PRKAG2, a gene that encodes the gamma-2 subunit of AMP-activated protein kinase. Mutations in PRKAG2 cause Cardiac Glycogenosis, the condition ATR 1072 is being studied in. The drug is a small molecule designed to address the effects of this genetic target.
ATR 1072 is developed by Atrium Therapeutics, Inc., which trades under the ticker RNA. The company is running the clinical program for this investigational small molecule in Cardiac Glycogenosis associated with PRKAG2 syndrome.
ATR 1072 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any regulatory agency. The Phase 1 program includes one active, recruiting trial with a total planned enrollment of 37 participants.
ATR 1072 is being studied in one Phase 1 trial, NCT07738107, titled ATR 1072 in Participants With PRKAG2 Syndrome. The trial is recruiting in the United States, enrolls 37 adults aged 18 and older of all sexes, and uses a controlled design without randomization or double blinding.